2. Academic Validation
  3. CD36 is a co-receptor for hepatitis C virus E1 protein attachment

CD36 is a co-receptor for hepatitis C virus E1 protein attachment

  • Sci Rep. 2016 Feb 22;6:21808. doi: 10.1038/srep21808.
Jun-Jun Cheng 1 2,  Jian-Rui Li 1,  Meng-Hao Huang 1,  Lin-Lin Ma 1,  Zhou-Yi Wu 1,  Chen-Chen Jiang 1,  Wen-Jing Li 1,  Yu-Huan Li 1,  Yan-Xing Han 2,  Hu Li 1,  Jin-Hua Chen 1,  Yan-Xiang Wang 1,  Dan-Qing Song 1,  Zong-Gen Peng 1,  Jian-Dong Jiang 1 2
Affiliations

Affiliations

  • 1 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, 100050, China.
  • 2 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences &Peking Union Medical College, Beijing, 100050, China.
PMID: 26898231 DOI: 10.1038/srep21808
Abstract

The cluster of differentiation 36 (CD36) is a membrane protein related to lipid metabolism. We show that HCV Infection in vitro increased CD36 expression in either surface or soluble form. HCV attachment was facilitated through a direct interaction between CD36 and HCV E1 protein, causing enhanced entry and replication. The HCV co-receptor effect of CD36 was independent of that of SR-BI. CD36 monoclonal Antibodies neutralized the effect of CD36 and reduced HCV replication. CD36 inhibitor sulfo-N-succinimidyl oleate (SSO), which directly bound CD36 but not SR-BI, significantly interrupted HCV entry, and therefore inhibited HCV replication. SSO's Antiviral effect was seen only in HCV but not in other viruses. SSO in combination with known anti-HCV drugs showed additional inhibition against HCV. SSO was considerably safe in mice. Conclusively, CD36 interacts with HCV E1 and might be a co-receptor specific for HCV entry; thus, CD36 could be a potential drug target against HCV.

Figures
Products